Brain-selective Kinase 2 (BRSK2) Phosphorylation on PCTAIRE1 Negatively Regulates Glucose-stimulated Insulin Secretion in Pancreatic β-Cells*

Background: BRSK2 has never reported to be functional in pancreatic islets. Results: BRSK2 interacts with PCTAIRE1 and phosphorylates it at Ser-12. Knockdown of BRSK2 augmented low glucose-stimulated insulin secretion. Conclusion: BRSK2 negatively regulates insulin secretion in β-cells via a PCTAIRE1-dependent mechanism. Significance: This study reveals a novel function of BRSK2 in insulin secretion and uncovers its related regulation mechanism. Brain-selective kinase 2 (BRSK2) has been shown to play an essential role in neuronal polarization. In the present study, we show that BRSK2 is also abundantly expressed in pancreatic islets and MIN6 β-cell line. Yeast two-hybrid screening, GST fusion protein pull-down, and co-immunoprecipitation assays reveal that BRSK2 interacts with CDK-related protein kinase PCTAIRE1, a kinase involved in neurite outgrowth and neurotransmitter release. In MIN6 cells, BRSK2 co-localizes with PCTAIRE1 in the cytoplasm and phosphorylates one of its serine residues, Ser-12. Phosphorylation of PCTAIRE1 by BRSK2 reduces glucose-stimulated insulin secretion (GSIS) in MIN6 cells. Conversely, knockdown of BRSK2 by siRNA increases serum insulin levels in mice. Our results reveal a novel function of BRSK2 in the regulation of GSIS in β-cells via a PCTAIRE1-dependent mechanism and suggest that BRSK2 is an attractive target for developing novel diabetic drugs.

Brain-selective kinase 2 (BRSK2, 4 also known as SAD-A) is a member of the AMP-activated protein kinase (AMPK) subfam-ily of serine/threonine kinases (1). BRSK2 and closely-related BRSK1 (also named SAD-B) are orthologs of SAD-1 in Caenorhabditis elegans (2,3). They were originally identified as genes specifically expressed in the brain, with an essential function in neuronal polarization (2). Neurons of SAD-AB Ϫ/Ϫ -null mutant mice have extended axons, and neurons from hippocampus-and cortex-specific mutant mice also failed to form distinct axons and dendrites in culture (2). Subsequently, BRSK1 was identified to be a novel SV (synaptic vesicle), and active zone cytomatrix-associated protein kinase that is involved in the regulation of neurotransmitter release; it most likely functions by phosphorylating the active zone protein and vesicle priming factor RIM1, among other potential targets in SVs and/or active zones (3).
AMPK has been shown to be a potential therapeutic target for type 2 diabetes (4), largely due to its regulatory function in glucose and lipid metabolism. AMPK undergoes activation at low glucose levels in pancreatic ␤-cells to regulate the dynamics of insulin-containing secretory vesicles and hence, insulin secretion (5,6). Activation of AMPK has been reported to impair glucose-induced insulin secretion (GSIS) and survival of pancreatic ␤-cells and islets (7)(8)(9). AMPK is activated by high AMP (and low ATP) concentrations through multiple mechanisms, through modulation of both the intrinsic kinase activity and its phosphorylation and activation by an upstream kinase, AMPK kinase (AMPKK) (10 -12). One such AMPKK is LKB1, a tumor suppressor kinase implicated in the pathogenesis of Peutz-Jeghers Syndrome (13)(14)(15). LKB1 has been reported to phosphorylate and activate 13 AMPK family members, including BRSK2 (1). Mutation of residue Thr-174 within the T-loop of BRSK2 alters its kinase activity (1). Although BRSK2 belongs to the AMPK family, it has not been shown to play a role in regulating insulin secretion and/or energy metabolism.
PCTAIRE1 is a serine/threonine kinase, which was originally identified as a Cdc2-like kinase (16,17). As an uncharacterized branch of the cyclin-dependent kinase (CDK) family, PCTAIRE1 has two isoforms in higher organisms, PCTAIRE2 and PCTAIRE3 (17), both of which contain a large N-terminal domain. PCTAIRE kinases are ubiquitously expressed, and it has been found to be predominantly expressed in terminally differentiated cells and transformed cell lines (18,19). They are not activated by any known cyclins (18) as a result of a serine to cysteine mutation in their conserved cyclin-binding consensus motif. Recently, a novel cyclin CYY-1 was identified and shown to be essential for PCTAIRE1 activity targeting presynaptic components to axons (20). PCTAIRE1 modulates secretory cargo transport by interacting with the COPII complex (21), and regulates secretion of growth hormone from PC12 cells through phosphorylation of residue Ser-569 of the N-ethylmaleimide-sensitive fusion protein (NSF) (22).
In this study, we uncovered new functions of BRSK2 and PCTAIRE1 in pancreatic ␤-cells. We demonstrated that both kinases are highly expressed in human pancreatic islets and MIN6 murine ␤-cell line. Importantly, we found that PCTAIRE1 is a substrate of BRSK2 and the phosphorylation of PCTAIRE1 by BRSK2 plays a crucial role in regulating insulin secretion in response to glucose.
Northern Blot Analysis-Northern blot was performed as previously described (2) using a full-length human BRSK2 cDNA hybridization probe. Human multiple tissue Northern blots, containing 2 g/lane of poly (A)-purified mRNA normalized for ␤-actin expression, were purchased from Clontech.
Tissue Source-Human pancreatic tissues were obtained from the pancreatic tumor patients, who had undergone resection at General Surgery Unit of Zhongshan Hospital at Fudan University. We carried out immunostaining in pancreatic tumor tissues that contain a large region of normal pancreatic exocrine and endocrine parts. And these patients were all informed and approved before using their tissues. All tissues were used in accordance with applicable laws and with the Declaration of Helsinki for research involving human tissues.
Mice tissues were isolated from adult BALB/c mice (male, 6-week-old). Mice experiments followed the principles of laboratory animal care and were approved by Fudan University Life Science Ethic Committee.
Intravenous siRNA Delivery, ELISA Assay, and Glucose Tolerance Tests-6-week-old BALB/c mice (20 g body weight) received tail-vein injections of saline, control siRNA, or siRNA against BRSK2 for one to three consecutive days. Mice were housed with 4 -6 animals per cage in a pathogen-free facility on a 12:12 h light/dark cycle. Everyday mice were injected at 4:00 pm and starved at 9:00 pm for 12 hours (water allowed). The siRNAs were administered at a total dose of 1000 g per mouse. Blood sample collections and islet isolations were performed 18 h after the last injection.
Following an overnight fast, mice were intraperitoneal (IP) injected with 2 mg glucose/g mice weight. Blood glucoses levels were assessed using a freestyle glucometer (Abbott). Serum insulin levels were assayed by a 96-well plate ELISA assay (Linco Research). Serum glucagon levels were assessed by a 96-well plate ELISA assay (ALPCO Diagnostics). Tissues were harvested, snap-frozen, and stored at Ϫ80°C.
Isolated Pancreatic Islet and ␤-Cell Size Studies-Pancreatic islets were isolated by collagenase perfusion in situ, digested for 28 min, and then purified by single layer Histopaque (Sigma). Isolated islets were cultured in RPMI 1640 medium containing 11 mM glucose, 7.5% FCS, and 10 mM Hepes (Sigma). Islets of BRSK2-RNAi mice and control mice were isolated, spread and photographed using microscopy, followed by analysis using Image J software.
␤-Cells were marked by E-cadherin/insulin co-immunostaining. To calculate single ␤ cell size, the area of 50 -100 single ␤ cells from five islets of control or BRSK2-RNAi mice were measured using Image J software.
Measurements of Insulin Secretion-MIN6 cells were seeded in 24-well plates and transfected with 200 ng of plasmids encoding Myc-BRSK2, PCTAIRE1 or their mutant forms. 48 h after transfection, cells were washed in PBS and preincubated in glu-cose-free Krebs-Ringer bicarbonate (KRB) medium (125 mM NaCl, 4.74 mM KCl, 1 mM CaCl 2 , 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 , 5 mM NaHCO 3 , 25 mM HEPES, pH 7.4, with 0.1% BSA) at 37°C for 30 min. Cells were then incubated in KRB containing 3 mM or 25 mM glucose at 37°C for 30 min. The amount of insulin released into the incubation medium was assayed using a radioimmunoassay (Linco Research) following the manufacturer's protocol.
Yeast Two-hybrid Assay-A yeast two-hybrid assay was performed following the Matchmaker III system protocol (Clontech). The PCTAIRE1 clone was isolated from the adult human brain two-hybrid cDNA library using human full-length BRSK2 as bait, and identified by DNA sequencing. The interaction of BD (pGBKT7)-BRSK2 and AD (pGADT7)-PCTAIRE1 was verified by re-transformation in yeast.
Western Blot Analysis and Immunoprecipitation-For immunoprecipitation, cells were lysed in chilled lysis buffer (Cell Signaling lysis buffer with complete protease inhibitors). Lysates (200 g) were collected and incubated with 40 l protein G-Sepharose beads (Amersham Biosciences) and 1-2 g corresponding antibody for 4 -5 h at 4°C with gentle rotation. The samples were washed with cold lysis buffer, and subjected to Western analysis or to an in vitro phosphorylation assay (see below).
For Western blot analysis, cell and tissue extracts were prepared and measured using a detergent compatible protein assay kit (Bio-Rad). Samples were equally loaded onto a 4% to 10% or 12% gradient SDS-PAGE gel and transferred onto a nitrocellulose membrane using standard techniques.
In Vitro Phosphorylation Assay-HA-BRSK2 overexpressed in 293T cells and immunoprecipitated with HA antibody were assayed for kinase activity (see immunoprecipitation assay) by incubating with recombinant GST-PCTAIRE1 (full length, deletion mutants and site-directed mutants) as substrates in kinase buffer (20 mM MOPS, PH 7.4, 15 mM MgCl 2 , 100 M ATP) containing 1 Ci of [␥-32 P]ATP at 30°C for 30 min. Samples were separated on SDS-PAGE and visualized by autoradiography.
Fusion Protein and Pull-down Assay-GST-PCTAIRE1, its fragments and/or mutant proteins were expressed in the BL21 (DE3) strain and purified using a glutathione-Sepharose 4B column following the manufacturer's instruction (Amersham Biosciences). GST-tagged fusion proteins or GST proteins were incubated with 40 l beads and 200 g lysates from 293T cells expressing HA-BRSK2 for 4 h at 4°C. Proteins were then subjected to SDS-PAGE and immunoblotted using anti-HA antibody. The fusion proteins were also detected by Western blot using an anti-GST antibody.
Immunofluorescence-MIN6 cells were transfected with PCMV-Myc-BRSK2 and/or the EGFPN1-PCTAIRE1 for 48 h, fixed with 4% paraformaldehyde and permeabilized with Triton X-100. After washes with TBS, cells were stained with DAPI (Sigma) and stained with an anti-Myc antibody followed by fluorescein isothiocyanate-conjugated goat antimouse antibody. Images were acquired with a Leica confocal microscope.

RESULTS
Expression and Activity of BRSK2 in Pancreatic Islets and MIN6 ␤-Cells-Using Northern blot analysis, we determined the level of mRNA of BRSK2 in a number of human tissues. We were surprised to find that BRSK2 mRNA was expressed at an even higher level in pancreas than in the brain (Fig. 1A) (2, 3). A similar expression pattern was seen at the protein level by Western blot analysis using a newly generated antibody against BRSK2 ( Fig. 1B and supplemental Fig. S1, A and B). Immunohistochemical analysis of human pancreatic tissue with BRSK2 antibody also revealed abundant staining in pancreatic islets and ducts ( Fig. 2B and supplemental Fig. S1C). Moreover, BRSK2 was found to be specifically co-localized with insulin, but not glucagon (Fig. 1C). In agreement with those observations, we also found that BRSK2 was highly expressed in MIN6, a murine ␤-cell line (Fig. 1D), and in homogenates of isolated mouse islets (Fig. 4A). Importantly, when MIN6 cells were treated with varying concentrations of glucose for 5 h, the expression of BRSK2 was down-regulated in a dose-dependent manner, which was accompanied by decreases in the phosphorylation of CDC25C ( Fig. 1E and supplemental Fig. S1, D and E). These preliminary observations hinted at a potential role of BRSK2 in pancreas, raising the possibility that it might be involved in the regulation of insulin secretion.
Identification of PCTAIRE1 as a Novel BRSK2-interacting Protein-To gain insights into the function of BRSK2, we searched for its interacting proteins using yeast two-hybrid system and identified PCTAIRE1 as a novel BRSK2-interacting protein. The full-length PCTAIRE1 cDNA was cloned by PCR, and the interaction between PCTAIRE1 and BRSK2 was reconfirmed by the two-hybrid assay ( Fig. 2A). Similar to BRSK2 (2, 3), PCTAIRE1 was previously known to regulate neurite outgrowth and secretion of growth hormones (18,22). Unlike BRSK2, PCTAIRE1 is ubiquitously expressed with the highest abundance in terminally differentiated cells and transformed cell lines (18,19). Using immunohistochemical staining and Western blot analysis, we found that PCTAIRE1 was highly expressed in both pancreatic islets and MIN6 cells ( Fig. 2B and supplemental Fig. S2A). In contrast to PCTAIRE1, the other isoforms, PCTAIRE2 and PCTAIRE3, were not detected in MIN6 cells (supplemental Fig. S2A).
We next determined the specificity of the interaction between BRSK2 and PCTAIRE1 using an in vitro binding assay. Thus, recombinant HA-BRSK2 was purified and incubated with immobilized GST-PCTAIRE1 or GST as a control. HA-BRSK2 was pulled down by GST-PCTAIRE1, but not by GST (Fig. 2D). The BRSK2-PCTAIRE1 interaction was further verified by co-immunoprecipitation using an anti-PCTAIRE1 antibody in MIN6 cells (Fig. 2E). HA-BRSK2 and Myc-PCTAIRE1 were also coimmunoprecipitated (supplemental Fig. S2B). Both proteins were found to be localized in the cytoplasm in MIN6 cells (Fig. 2F). We then employed the GST pull-down assay to determine the domain in PCTAIRE1 that mediates its interaction with BRSK2. We generated three PCTAIRE1 deletion mutants, GST-PCTAIRE1-Fa, Fb, and Fc, corresponding to aa1-128, aa129 -289, and aa290 -496, respectively (Fig. 2C). As shown in Fig. 2D, BRSK2 was specifically captured by immobi-lized GST-PCTAIRE1, GST-PCTAIRE1 Fb (aa129 -289) and Fc (aa290 -496), but not by Fa (aa1-128), indicating that BRSK2 interacts with PCTAIRE1 mainly through its kinase and C-terminal domains, located in the aa129 -496 region.
Phosphorylation of PCTAIRE1 by BRSK2 at Ser-12-Analysis by a Scansite Motif Scanner predicted that PCTAIRE1 may be a substrate for the serine/threonine kinase CAMK2 (Ca 2ϩ /calmodulin-dependent kinase 2). Because BRSK2 is a serine/threonine kinase belonging to the AMPK subfamily of the CAMK family (23), we investigated whether BRSK2 is capable of phosphorylating PCTAIRE1.
BRSK2 has been reported to preferentially phosphorylate serine/threonine residues within the (L/M/I/F/V)X(R/K/ H)XX(S/T) consensus sequence (1). Interestingly, PCTAIRE1 contains 9 BRSK2 phosphorylation consensus sequences, further suggesting that PCTAIRE1 may be a substrate of BRSK2 (Fig. 2C). Using an in vitro kinase assay, we found that BRSK2 phosphorylated PCTAIRE1 while the catalytically inactive mutant did not (Fig. 3). We took advantage of the three deletion mutants of PCTAIRE1, each of which contained three consensus BRSK2 phosphorylation sequences (Fig. 2C). Of the three deletion mutant proteins, GST-PCTAIRE1 Fa (N-terminal domain, aa1-128), but not GST-PCTAIRE1 Fb or Fc (kinase domain and C-terminal domain, aa129 -496) was phosphorylated by wild type, but not catalytically inactive BRSK2 (Fig. 3). To further narrow down the site(s) of BRSK2 phosphorylation in PCTAIRE1 Fa domain, we mutated the putative serine residues into alanines and subjected each mutant to the in vitro kinase assay. While BRSK2 phosphorylated S78A and S119A mutants, it failed to phosphorylate the S12A mutant (Fig. 3), suggesting that serine 12 constitutes the main phosphorylation site by BRSK2.
BRSK2 Negatively Regulates Insulin Secretion in MIN6 Cells-The selective expression of BRSK2 in pancreatic tissue and MIN6 cell line prompted us to investigate its potential role in regulating insulin secretion. We used glucose-induced insulin secretion in MIN6 cells as the model system (24). MIN6 cells showed an ϳ3-fold increase in insulin secretion when the glucose concentration in the medium was increased from 3-25 mM (Fig. 4A).
We transiently expressed Myc-tagged wild-type BRSK2, a constitutively active mutant T174E or a kinase-dead mutant K48M of BRSK2 in MIN6 cells and measured insulin secretion upon incubation with or without glucose for 36 h. Each of the mutant proteins was found to be expressed at a comparable level by Western blot analysis (Fig. 4A). Overexpression of BRSK2 and the constitutively active T174E mutant had no significant effect on insulin secretion when MIN6 cells were treated with 3 mM glucose, but caused a marked reduction of insulin secretion when glucose concentration was increased to 25 mM glucose (Fig. 4A). In contrast, the inactive K48M form had no effect on insulin secretion in response to 3-25 mM glucose (Fig. 4A).
Reciprocally, down-regulation of BRSK2 by siRNA, as confirmed by Western blot analysis (Fig. 4A), caused a marked increase in insulin secretion from MIN6 cells at 3 mM glucose, but not 25 mM glucose (Fig. 4A). Together, these results

FIGURE 1. Expression and activity of BRSK2 in pancreatic islets and MIN6 ␤-cells.
A, Northern blot analysis using full length BRSK2 probe showed BRSK2 expression in human brain and pancreatic tissues. B, Western blot of BRSK2 with high level in mouse pancreas besides in brain. C, immunostaining of human pancreatic tissues with anti-BRSK2 antibody or/and anti-insulin antibody or anti-glucagon antibody followed by fluorescein isothiocyanate-conjugated goat anti-rabbit/mouse antibody. Scale bar, 25 m. D, expression of BRSK2 in MIN6 ␤-cells compared with other cell lines by Western blot with BRSK2 antibody. E, expression and activity of BRSK2 was inhibited by elevated glucose concentrations for 5 h in MIN6 cells as visualized by Western blot using BRSK2, CDC25C, or phosphor-CDC25C Ser-216 antibody. CDC25C F (CDC25C fragment, aa143-253) was phosphorylated on Ser-216 by BRSK2 and used as substrate for BRSK2 activity detection according to our unpublished data (supplemental Fig. S1E). Loading of each lane was controlled by immunolabeling of ␤-actin. strongly suggested that BRSK2 played a negative regulatory role in glucose-stimulated insulin secretion (GSIS) in MIN6 cells.
BRSK2 Regulates Insulin Secretion in MIN6 Cells via PCTAIRE1 Depending on Its Kinase Activity-Given that BRSK2 interacted with and phosphorylated PCTAIRE1, we asked whether PCTAIRE1 and its kinase activity are critical in mediating the effect of BRSK2 on insulin secretion in MIN6 cells. Myc-tagged wild-type PCTAIRE1, and the phosphorylation-defective PCTAIRE1-S12A and phosphorylation-mimetic S12E mutants were transiently transfected into MIN6 cells. The constitutively active (S153A) and the kinase-dead (K194M) PCTAIRE1 mutants were also employed (18). Similar to BRSK2 and its active T174E form, overexpressing wild type PCTAIRE1 and its active forms S153A mutants or BRSK2 phosphorylation-mimetic S12E mutants markedly inhibited insulin secretion at 25 mM, but not at 3 mM glucose in MIN6 cells (Fig. 4B). In contrast, overexpression of the phosphorylation-defective PCTAIRE1 S12A or the kinase-dead (K194M) mutant did not affect insulin secretion (Fig. 4B). Similar to BRSK2, siRNA down-regulation of PCTAIRE1 (Fig. 4B) significantly stimulated insulin secretion from MIN6 cells at 3 mM glucose, but not at 25 mM glucose (Fig. 4B). These results suggested that BRSK2 phosphorylation of PCTAIRE1 at Ser-12 is required for its regulation of insulin secretion from MIN6 cells.
To verify that BRSK2 lies upstream of PCTAIRE1 in the regulation of glucose-stimulated insulin secretion, PCTAIRE1 was expressed in MIN6 cells in which BRSK2 had been knocked down by RNAi and PCTAIRE1 expression was found to partially reverse the effect of BRSK2 knockdown on insulin secretion (Fig. 4B). In contrast, down-regulation of PCTAIRE1 in MIN6 cells overexpressing BRSK2 failed to inhibit insulin secretion at 25 mM glucose (Fig. 4B). These results suggested that PCTAIRE1 mediated the regulatory effect of BRSK2 on insulin secretion in MIN6 cells. Together, these observations indicated that BRSK2 regulated insulin secretion in MIN6 cells through phosphorylating PCTAIRE1 kinase.
Attenuation of BRSK2 in Mice Islets Increases Serum Insulin Levels-Finally, we attempted to verify the role of BRSK2 in regulating insulin secretion in vivo. It has been shown that intravascular delivery of fluorophoro-labeled siRNA could silence Ins2 expression in the endocrine pancreas (25). We used a similar approach (tail vein injection) to delivering BRSK2 siRNA into mice (BRSK2-RNAi mice), which led to ϳ1.8-fold reduction in BRSK2 protein levels in mouse pancreatic islets (Fig. 5A). The down-regulation of BRSK2 resulted in a significant increase (1.5-1.8-fold) in serum insulin levels relative to the control mice (Fig. 5B), but no significant changes in mouse serum glucagon levels (supplemental Fig. S3A). Importantly, BRSK2-RNAi mice displayed improved glucose tolerance (Fig.  5C) and possibly showed a tendency toward enlarged islets and increased ␤-cell size (supplemental Fig. S3, B and C). These findings suggest a physiological function of BRSK2 in the control of insulin secretion and possibly pancreatic islet homeostasis.

DISCUSSION
In this study, we provide the first line of evidence that BRSK2 and PCTAIRE1 are selectively expressed in high abundance in pancreatic tissues and MIN6 ␤-cells. At high, but not low concentrations, glucose reduced BRSK2 activity in MIN6 ␤-cells. Upon activation, BRSK2 interacted with and phosphorylated PCTAIRE1 on its Ser-12 residue, leading to inhibition of insulin secretion in MIN6 cells. Conversely, knockdown of BRSK2 resulted in a significant increase in serum insulin levels and a tendency toward enlarged islets and increased ␤-cell size in mice. These findings identify a novel signaling pathway involved in the regulation of GSIS in pancreatic ␤-cells.
It has been previously shown that BRSK2 is activated by the kinase LKB1 (1). LKB1 is a tumor suppressor implicated in Peutz-Jeghers Syndrome (15) and has been implicated in a number of distinct biological processes. Loss of LKB1 in adult ␤-cells has been recently shown to increase ␤-cell mass and insulin secretion, and enhance glucose tolerance in mice mainly through the AMPK-mTOR pathway (26,27). The existence of other pathways by which LKB1 restricts acute insulin secretion in vivo was also suggested. Given that BRSK2 is a downstream phosphorylation target of LKB1 (1), LKB1 may also activate BRSK2 to down-regulate insulin secretion in ␤-cells.
BRSK2 knockdown by siRNA in mice was found to increase serum insulin levels, improve GTT and show a tendency of increased islet/␤-cell size, further supporting a physiological role of BRSK2 in the regulation of insulin secretion and pancreatic homeostasis. This is consistent with the findings by Hezel et al. that Lkb1 deficiency in pancreas reduced expression of BRSK1 and BRSK2 in pancreatic tissues (28), though another group failed to detect BRSK1/2 expression in islets isolated from 12-week-old male C57B1/6 mice (29). While both adult p-Lkb1 mice (28) and transgenic mice lacking LKB1 (29) exhibited improved GTT and p-Lkb1 mice at PD1 (postnatal day 1) have smaller islets (28), the latter showed increased plasma insulin levels and increased ␤-cell mass with impaired GSIS (29). Whether the increased insulin secretion is due to the augmented islet/␤-cell size remains to be verified.
The expression pattern of BRSK2 is also unique and interesting. We noticed that BRSK2 in pancreas tissue was highly abundant. The positive band of BRSK2 mRNA showed distribution from 1.5-10 kB, suggesting that it might have several multisplice variants in pancreas. According to the Ensembl database, BRSK2 contains about 11 variants which are likely to code proteins. This explains the observations that while we detected BRSK2 as a 75-kDa protein, others have found it to be a 50-kDa protein in islets (26). It also raised the interesting question of whether different BRSK2 variants have distinct functions.
PCTAIRE kinases are structurally related to CDKs, but have not been shown to interact with any known cyclin or cyclin-like proteins (16 -18). Hence, their role in cell cycle regulation has remained unclear. More recent studies, however, have demonstrated that PCTAIRE1 modulates the secretory cargo transport (21), phosphorylates NSF (N-ethylmaleimide-sensitive factor) and inhibits growth hormone release from PC12 cells (22). It has been suggested that PCTAIRE1 is a component of the NSF-SNAP-SNARE complex and plays a regulatory role in Ca 2ϩ -dependent exocytosis through NSF phosphorylation (22). NSF is an essential factor for vesicular transport and fusion of presynaptic membranes (30,31), which acts as a molecular chaperone to hydrolyze ATP and alters the conformation of the SNARE complex (32). Complex formation between NSF, SNAP, and SNARE membrane receptors plays an important role in membrane fusion and constitutes an essential mediator of many transport reactions (33). Similar to neurotransmitter release (34), the mechanism underlying insulin secretion in ␤-cells is also regulated by the SNARE complex (35,36). The current study demonstrates that PCTAIRE1 functions downstream of BRSK2 to inhibit insulin secretion at low glucose conditions. Importantly, this function of PCTAIRE1 depends on its kinase activity. We speculate that the ability of PCTAIRE1 to phosphorylate and inhibit NSF activity is also a major mechanism by which it regulates insulin secretion.
In summary, we propose a novel signaling pathway regulating insulin secretion in pancreatic ␤-cells (Fig. 5D). In our model, low levels of glucose activates the kinase activity of BRSK2 possibly by its upstream kinase LKB1. BRSK2, in turn, interacts with and phosphorylates PCTAIRE1 at Ser-12, leading to the inhibition of insulin secretion through phosphorylation of NSF and inactivation of the NSF-SNARE complex, which is required for insulin secretion from pancreatic ␤-cells. That knockdown of BRSK2 alone caused a significant increase in insulin secretion at low glucose concentration implied that BRSK2 dysfunction might be related to pancreatic ␤-cell dysfunction. Together with the highly specific expression of BRSK2 in pancreas and the brain, our study also suggests that BRSK2 may serve as a novel target for developing drugs for the treatment of diabetes.